Siemens Healthineers reported a solid start to fiscal 2026 with strong performance in Imaging and Precision Therapy, despite facing significant challenges in its Diagnostics segment, particularly in the Chinese market.

• Imaging and Precision Therapy achieved a robust 6% growth with operational margins expanding, effectively countering headwinds from tariffs and foreign exchange fluctuations.
• Diagnostics experienced a 3% revenue decline, primarily impacted by market shifts in China due to volume-based procurement and reimbursement changes.
• The Atellica portfolio surged by approximately 20%, now constituting 70% of core lab solution sales, with notable growth in the Americas.
• Siemens Healthineers received an investment-grade rating from Moody's as part of its ongoing preparations for deconsolidation from Siemens AG, underscoring strong financial health.
• The Elevating Health Globally strategy is gaining traction with positive feedback from clients, reflecting a commitment to address noncommunicable diseases through innovative healthcare solutions.